Schwab Charles Investment Management Inc. Buys 1,539 Shares of Intellia Therapeutics, Inc. (NTLA)
Schwab Charles Investment Management Inc. lifted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 6.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,903 shares of the company’s stock after purchasing an additional 1,539 shares during the period. Schwab Charles Investment Management Inc. owned about 0.07% of Intellia Therapeutics worth $380,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in NTLA. Acadian Asset Management LLC acquired a new stake in Intellia Therapeutics in the first quarter valued at $1,355,000. Russell Investments Group Ltd. acquired a new stake in Intellia Therapeutics in the first quarter valued at $137,000. Wells Fargo & Company MN raised its stake in Intellia Therapeutics by 231.7% in the first quarter. Wells Fargo & Company MN now owns 10,945 shares of the company’s stock valued at $154,000 after buying an additional 7,645 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Intellia Therapeutics by 5.6% in the first quarter. Bank of New York Mellon Corp now owns 31,676 shares of the company’s stock valued at $446,000 after buying an additional 1,682 shares in the last quarter. Finally, Airain ltd acquired a new stake in Intellia Therapeutics in the first quarter valued at $381,000. Hedge funds and other institutional investors own 46.52% of the company’s stock.
In other Intellia Therapeutics news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the company’s stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $16.24, for a total value of $2,436,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 12.80% of the company’s stock.
A number of analysts have weighed in on NTLA shares. Cann restated a “market perform” rating on shares of Intellia Therapeutics in a research note on Monday, July 17th. Wedbush restated an “outperform” rating and issued a $25.00 price target on shares of Intellia Therapeutics in a research note on Monday, May 15th. TheStreet upgraded Intellia Therapeutics from a “d+” rating to a “c-” rating in a research note on Thursday, July 6th. Barclays PLC started coverage on Intellia Therapeutics in a research note on Wednesday. They issued an “overweight” rating and a $29.00 price target on the stock. Finally, Oppenheimer Holdings, Inc. started coverage on Intellia Therapeutics in a research note on Tuesday, July 18th. They issued a “market perform” rating on the stock. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Intellia Therapeutics presently has an average rating of “Buy” and a consensus target price of $25.43.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) traded up 3.02% during mid-day trading on Friday, reaching $22.20. The company’s stock had a trading volume of 204,598 shares. The stock’s market capitalization is $801.69 million. The stock’s 50 day moving average price is $17.76 and its 200 day moving average price is $15.09. Intellia Therapeutics, Inc. has a 1-year low of $10.83 and a 1-year high of $22.49.
Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.03. The firm had revenue of $5.90 million during the quarter, compared to analysts’ expectations of $5.83 million. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. Intellia Therapeutics’s quarterly revenue was up 40.5% on a year-over-year basis. Analysts expect that Intellia Therapeutics, Inc. will post ($1.78) EPS for the current fiscal year.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA).
Receive News & Stock Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related stocks with our FREE daily email newsletter.